The BioInnovation Institute Foundation (BII, part of the Novo Nordisk Foundation) in Copenhagen, Denmark, announced that it will be supporting three international start-up companies, amogst them MyoPax. The ventures are strategically aligned with the incubator’s focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
MyoPax is starting its operational activities in Berlin and Copenhagen. The spin-off originates from the translational ecosystem of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, the Charité Universitätsmedizin Berlin and the Berlin Institute of Health (BIH). MyoPax is now funded with a risk-free convertible loan of 1.3 million euros and is going to be part of the BII’s community of life science start-ups in Copenhagen.
